Author: Avalon Health Economics LLC

Paying for Specialty Pharmaceuticals: The Case of Injectable Oncology Drugs
April 28, 2015 - 2:51 pm, by
According to the American Cancer Society, the financial costs of cancer are high for both the person with cancer and for society as a whole. The National Institutes of Health (NIH) estimated the 2009 overall annual costs of cancer in the U.S. to be $216.6 billion, consisting of $86.6 billion in direct costs and $130...
Avalon CEO John Schneider presents on “The Economics of Molecular Diagnostics” at the University of California Berkeley
April 27, 2015 - 11:34 am, by
Avalon CEO John Schneider presents on “The Economics of Molecular Diagnostics” at the University of California Berkeley’s School of Public Health. The lecture covered the basics of molecular diagnostics followed by a more detailed assessment of the costs and benefits of molecular diagnostics. Discussions centered around the value of diagnostics, and how payers and patients...
Book Review: “Purchasing Medical Innovation: The Right Technology, for the Right Patient, at the Right Price,” by James C. Robinson
March 22, 2015 - 2:49 pm, by
The demand for medical care services in the U.S. has long been the envy of other industries. Americans are generally not accustomed to going without, typically despise most non-market forms of rationing, and don’t like government telling them what they can and can’t have. Beneath this culture of consumption lie several layers of public and...
Integration of Novel Diagnostics into Clinical Practice
February 28, 2015 - 2:46 pm, by
Similar to drug and device markets, a critical part of the success of novel diagnostics is educating providers on clinical and therapeutic utility. However, unlike pharmaceutical drugs, the ordering of a diagnostic test does not necessarily imply a change in provider behavior or a change in treatment strategy. It’s a bit like whether a tree...
Avalon team publishes study of the U.S. cost impact of procalcitonin testing in acute respiratory infections
February 26, 2015 - 11:32 am, by
Avalon team publishes study of the U.S. cost impact of procalcitonin testing in acute respiratory infections. In the inpatient setting, the costs of procalcitonin guided compared to usual care for the one million member cohort was $ 2,083,545, compared to $ 2,780,322, resulting in net savings of nearly $ 700,000 to the IDN for 2014....
The State of the Union and Innovation in Molecular Diagnostics
January 22, 2015 - 11:41 am, by
During the U.S. “State of the Union” address this past week, President Obama devoted some time to emphasizing the importance of “personalized medicine,” referring to the rapid pace of innovation and the high expectations for the role molecular diagnostics in the U.S. health care system: “I want the country that eliminated polio and mapped the...
How Should Health Care Providers Measure and Market the Value of their Services?
December 31, 2014 - 2:23 pm, by
There was a time when we did not spend a lot of time worrying about the quality of the health care services we received. Our families went to the doctor who was known as a “good doctor” and we received treatment in the nearby hospital known as a “good hospital.” An endorsement or two from...
The Long Reach of a Devastating Virus
November 24, 2014 - 2:18 pm, by
As a follow-up to our previous blog (October 2014), we are revisiting the topic of Ebola because this public health crisis has drawn attention to two very important public health issues: (1) the ever-present global danger of infectious diseases, and (2) the critical role of the public health and health system infrastructures in preventing and...
Health Care Reform in Sub-Saharan Africa
October 28, 2014 - 1:57 pm, by
The recent Ebola epidemic in Africa has served as a reminder of the vulnerability of public health systems in handling unexpected health problems, especially when basic access to care and day-to-day health problems remain a challenge. Unlike its northern counterpart, Sub-Saharan Africa (SSA) continues to experience a disproportionate burden of disease, influenced by the intersection...
John Rizzo, PhD, joins Avalon Health Economics as a Consultant
September 13, 2014 - 11:29 am, by
John Rizzo, PhD, joins Avalon Health Economics as a Consultant. In addition to his role as Consultant with Avalon Health Economics, Dr. Rizzo is Professor of Economics and Preventive Medicine at Stony Brook University (NY) and Chief Economist at the Long Island Association. His research interests include applied economic studies of health care markets and...
Do NOT follow this link or you will be banned from the site!